Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ISIS Pharmaceuticals, Inc. : Law Offices of Howard G. Smith Announces Class Action Lawsuit Against ISIS Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/26/2013 | 08:35pm CEST

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all purchasers of the common stock of ISIS Pharmaceuticals, Inc. ("ISIS" or the "Company") (NASDAQ:ISIS) between March 29, 2012 and October 15, 2012, inclusive (the "Class Period").

ISIS engages in the discovery and development of drugs utilizing antisense technology, primarily to treat cardiovascular, metabolic, severe and rare diseases, as well as cancer. The Complaint alleges that throughout the Class Period the Company and certain of its executive officers issued materially false and misleading statements regarding the safety and efficacy of the Company's flagship product, Kynamro (mipomersen sodium), for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Specifically, the Complaint alleges that defendants, through a series of materially false and misleading statements regarding the safety and efficacy of the product, and reportedly positive results from Kynamro's clinical trials, conditioned investors to believe that Kynamro would receive approval from the U.S. Food and Drug Administration (FDA).

On October 16, 2012 the FDA published a clinical briefing document raising concerns regarding the safety and efficacy of Kynamro, noting among other things, abnormal growths or neoplasms developed in 3.1% of patients treated with Kynamro, as compared to only 0.9% of patients who took a placebo; that the data submitted by the Company was limited by a small sample size and a short treatment time, and that during the clinical testing two patients treated with Kynamro died of heart attacks and another patient died of acute liver failure. The FDA report concluded that this "imbalance in neoplasms will need to be assessed further in on-going and future studies and post-marketing (if approved)," and that "the potential for a contributing effect of mipomersen cannot be ruled out" in the patient deaths. As a result of these disclosures, ISIS shares declined nearly 22%, to close at $10.27 on October 16, 2012.

No class has yet been certified in this action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased ISIS common stock during the Class Period, you have certain rights, and have until February 26, 2013 to move for lead plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
01:01p IONIS PHARMACEUTICALS : to Present at Needham Healthcare Conference
03/28 AKCEA THERAPEUTICS : Announces Three Additions to Board of Directors
03/27 IONIS PHARMACEUTICALS,INC. (NASDAQ : IONS) Files An 8-K Other Events
03/27 IONIS PHARMACEUTICALS : Akcea Therapeutics Files Registration Statement for Prop..
03/27 IONIS PHARMACEUTICALS INC : Other Events (form 8-K)
03/23 IONIS PHARMACEUTICALS : Reports from Ionis Pharmaceuticals Highlight Recent Find..
03/17 IONIS PHARMACEUTICALS : ` Latest Attempt To Weaponize Antisense Against Cancer
03/16 IONIS PHARMACEUTICALS : Reports from Ionis Pharmaceuticals Advance Knowledge in ..
03/08 Goldberg Law PC Announces an Investigation of Ionis Pharmaceuticals Inc. and ..
03/06 Levi & Korsinsky, LLP Announces the Commencement of an Investigation of Ionis..
More news
Sector news : Biotechnology & Medical Research - NEC
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Financials ($)
Sales 2017 369 M
EBIT 2017 -38,1 M
Net income 2017 -74,5 M
Finance 2017 109 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 12,7x
EV / Sales 2018 10,4x
Capitalization 4 808 M
More Financials
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 13
Average target price 46,7 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Senior VP-Finance
Joseph H. Wender Independent Director
Frederick T. Muto Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%4 808
INCYTE CORPORATION39.10%28 429
QUINTILES IMS HOLDINGS..3.48%18 567
LONZA GROUP AG3.12%10 618
CELLTRION, INC.--.--%9 982
SEATTLE GENETICS, INC.22.17%9 187
More Results